Xalatan(キサラタン)[]の個人輸入代行

お探しの製品名を正確にご入力ください:
総取扱点数 7,278件 (Last update 2017/11/25)
医薬品の個人輸入 TOP > キサラタン(Xalatan)の個人輸入代行 - ラタノプロスト(Latanoprost)
Xalatan(キサラタン)
写真はイメージです。実際にお届けするものと外観が異なる可能性があります。 Xalatan(キサラタン)のQRコード
スマホ用QRコード

Xalatan(キサラタン)

General Name
Suitable for 緑内障治療薬
Documents
adobe
資料 1
Related News

Product details for Xalatan(キサラタン)

電話・FAXでご注文の際は下記IDをお申し付けください。
ID 冷蔵/薬監 Type Amount Units/wrapping Manufacturer Manufacturer country Shipping country Unit price Delivery date Click to order
29412-36775
冷蔵
点眼液 0.05mg/2.5ml 1 Pharmacia & Upjohn スイス スイス 9,400 yen 10days
29412-36776
冷蔵
点眼液 0.05mg/2.5ml 3 Pharmacia & Upjohn スイス スイス 16,800 yen 10days

The attention at the time of the order the Xalatan(キサラタン)

  1. Please acknowledge that we do not refund or accept returned pharmaceuticals in any way once payment has been made.
    ※Defective product or mis-delivery are exceptions.
  2. This medical product is required Yakkan Syoumei if a doctor order for treatment or research Yakkan Shoumei commission is 20,000 YEN.
  3. A consumption tax occurs at the time of entry to import goods more than 10,000 yen. Please confirm it later because it becomes the direct request from a delivery supplier separately
  4. This medical product would be quantity restriction without Yakkan Syoumei Please click here for details.
  5. Because of the regulations, we can not provide detailed information including effects, side effects and dosage.

Other charges than mentioned above for Xalatan(キサラタン)

  For doctors For patients
Shipping fee 冷蔵FedEX:12,000 yen
*Domestic chilled delivery fee may be chargeable depending on the size of the package and destination
冷蔵FedEX:12,000 yen
*Domestic chilled delivery fee may be chargeable depending on the size of the package and destination
薬監証明手数料 20,000 yen -
Consumption tax Will be charged directly by delivery company Will be charged directly by delivery company
※送料、薬監証明手数料については、輸入数量に関わらず1回の輸入につき一律料金とさせて頂いております。
get adobe reader
Xalatan(キサラタン) のことなら医薬品個人輸入代行のアイアールエックス・メディシンへ。
 

Xalatan(キサラタン) 関連ニュース&トピックス